Insulin – Talk Bio

Actionable Insights Powered by AI

Pharma’s wins and losses in Trump’s sprawling executive order on drug prices

1 week ago talkbio0Tagged drug price, Industry, Insulin, IRA, losses, Mediation, Medicare, Prices, small molecule drugs

Medicare, Medicare, Industry, drug price, Mediation, small molecule drugs, losses, IRA, Insulin, Prices

Back to the drawing board for Vertex’s ‘cells plus device’ diabetes programme

3 weeks ago talkbio0Tagged Cell Therapy, Clinical Trials, Failure (biologic function), implantable device, Insulin, production, VX-264, zimislecel

Vertex Pharmaceuticals, VX-264, type 1 diabetes, cell therapy, implantable device, clinical trial failure, zimislecel, insulin production

Sanofi Invests €1 Billion in Beijing to Enhance Insulin Production Capacity

5 months ago talkbio0Tagged Beijing, Drug Industry, Insulin, Investments, production, sanofi

Sanofi, insulin production, Beijing, investment, pharmaceutical industry

Lilly’s Weekly Insulin Candidate Efsitora Alfa Shows Promising Results in Phase III Trials

7 months ago talkbio0Tagged Alfa, Diabetes, Diabetes Mellitus, Non-Insulin-Dependent, efsitora, Eli, Eli Lilly, Insulin, Phase 3 Clinical Trials, QWINT, Weekly

Eli Lilly, Efsitora Alfa, Weekly Insulin, Type 1 Diabetes, Type 2 Diabetes, Phase III Trials, QWINT Studies, Diabetes Treatment

EASD24: Lilly’s Weekly Insulin Efsitora Demonstrates Efficacy but Raises Hypoglycemia Concerns

7 months ago talkbio0Tagged Diabetes, Diabetes Mellitus, Non-Insulin-Dependent, EASD24, efsitora, Eli, Eli Lilly, Hypoglycemia, Insulin, insulin therapy, Weekly

Eli Lilly, EASD24, Weekly Insulin, Efsitora, Type 1 Diabetes, Type 2 Diabetes, Hypoglycemia, Insulin Therapy

Lilly’s Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Four Phase 3 Trials

8 months ago talkbio0Tagged Administration occupational activities, Alfa, Diabetes, efsitora, Eli, Eli Lilly, Hemoglobin A1c measurement, Insulin, insulin therapy, non-inferiority, once-weekly, Phase 3 trials

Eli Lilly, efsitora alfa, once-weekly insulin, diabetes management, Phase 3 trials, non-inferiority, A1C reduction, insulin therapy.

Eli Lilly’s Weekly Insulin Efsitora Alfa Shows Promising Results in Late-Stage Trials

8 months ago talkbio0Tagged Administration occupational activities, Alfa, Diabetes, efsitora, Eli, Eli Lilly, Insulin, insulin therapy, Phase 3 Clinical Trials, QWINT-1, QWINT-3, Weekly

Eli Lilly, weekly insulin, efsitora alfa, type 2 diabetes, Phase III trials, QWINT-1, QWINT-3, insulin therapy, diabetes management

Novo Nordisk Pursues FDA Filing for Once-Weekly Insulin and Semaglutide Combo After Icodec Rejection

8 months ago talkbio0Tagged Clinical Research, COMBINE-1, File (record), Icodec, IcoSema, Insulin, Nordisk, once-weekly, regulatory approval, semaglutide, United States Food and Drug Administration

Novo Nordisk, insulin icodec, semaglutide, FDA filing, type 2 diabetes, once-weekly insulin, IcoSema, COMBINE-1 study, regulatory approval

Novo Nordisk’s Once-Weekly Insulin Icodec Faces FDA Rejection and Manufacturing Concerns

8 months ago talkbio0Tagged Icodec, IcoSema, Insulin, Nordisk, once-weekly, Rejection (Psychology), semaglutide, United States Food and Drug Administration

Novo Nordisk, icodec, FDA rejection, once-weekly insulin, manufacturing issues, type 1 diabetes, type 2 diabetes, semaglutide, IcoSema

Sanofi Invests €1.3 Billion in Next-Generation Insulin Facility in Frankfurt

9 months ago talkbio0Tagged Diabetes, Frankfurt, Insulin, Insulin Facility, Investments, next-generation, sanofi

Sanofi, insulin facility, Frankfurt, diabetes treatment, next-generation insulin, €1.3 billion investment